Skip to content
Canine PeptideResearch peptides

Peptides for Rottweiler canine cancer support

The short answer

Rottweilers carry an elevated predisposition to canine cancer support. The compounds investigated for it are Thymosin Alpha-1, Fenbendazole, Ivermectin, PNC-27. At a typical Rottweiler weight of 35–60 kg (77–132 lb), this breed falls in the large / giant breed dosing class.

Canine cancer support in Rottweilers

Roughly one in four dogs develops cancer, and the figure approaches one in two past the age of ten. This is the most searched and least settled area in the peptide field, and it demands the most caution — for two reasons. First, several compounds that are useful elsewhere are actively contraindicated here: TB-500, IGF-1 LR3, and MGF all promote processes that tumours exploit. Second, the compounds under investigation for oncology use are the least evidenced on this site, with PNC-27 having no companion animal data at all. Nothing in this category should be undertaken outside a veterinary oncology relationship.

Dosing at Rottweiler body weight

Calculated for a 48 kg (106 lb) dog — the midpoint of the typical range for this breed.

CompoundDose at 48 kgFrequencyEvidence
Thymosin Alpha-12400–4800 mcg2-3x weeklyGood evidence
Fenbendazole2400 mg3 consecutive days weeklyEmerging evidence
Ivermectin14.4–28.8 mgDaily, or five days on / two days offEmerging evidence
PNC-2724–96 mg2-3x weeklyPreliminary / in vitro only

Weigh your dog rather than using a breed average — an individual Rottweiler can sit well outside the typical range. Use the dose calculator for an exact figure.

Common questions

What peptides are used for canine cancer support in Rottweilers?+

Thymosin Alpha-1, Fenbendazole, Ivermectin, PNC-27 are investigated for canine cancer support. No breed-specific pharmacological restriction is established for Rottweilers among these compounds.

How much should a Rottweiler be given?+

Rottweilers typically weigh 35–60 kg (77–132 lb), placing them in the large / giant breed class. Thymosin Alpha-1: approximately 2400–4800 mcg at 48 kg. Fenbendazole: approximately 2400 mg at 48 kg. Ivermectin: approximately 14.4–28.8 mg at 48 kg. PNC-27: approximately 24–96 mg at 48 kg. Weigh your dog rather than relying on a breed average.

Are Rottweilers more prone to canine cancer support?+

Yes. Rottweilers carry an elevated predisposition to canine cancer support. Investigational adjuncts alongside veterinary oncology care. The most experimental area covered here.

References

  1. 1.King R, Tuthill C Immune Modulation with Thymosin Alpha 1 Treatment. Vitamins and Hormones, 2016. PMID 27450734
  2. 2.Dominari A, Hathaway Iii D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology, 2020. PMID 33362999
  3. 3.Wei Y, Zhang J, Yan X, et al. Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. International Immunopharmacology, 2023. PMID 36812669
  4. 4.Guo Y, Chang H, Li J, et al. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway. Apoptosis, 2015. PMID 26002438
  5. 5.Wang F, Yu T, Zheng H, Lao X Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life. Scientific Reports, 2018. PMID 30120362
  6. 6.Dogra N, Kumar A, Mukhopadhyay T Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 2018. PMID 30093705
  7. 7.Duan Q, Liu Y, Rockwell S Fenbendazole as a potential anticancer drug. Anticancer Research, 2013. PMID 23393324
  8. 8.Nguyen J, Chong CR Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Research, 2024. PMID 39197912
  9. 9.Jung H, Lee J, Kim Y, et al. Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma. Current Issues in Molecular Biology, 2023. PMID 37998737
  10. 10.Pan T, et al. Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME signaling. Frontiers in Pharmacology, 2025. PMID 40756987
  11. 11.CANINE STUDYDiao H, Cheng N, Zhao Y, et al. Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling. BMC Veterinary Research, 2019. PMID 31375107
  12. 12.Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. American Journal of Cancer Research, 2018. PMID 29511601
  13. 13.Juarez M, Schcolnik-Cabrera A, Dominguez-Gomez G, et al. Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Cancer Chemotherapy and Pharmacology, 2020. PMID 32474842
  14. 14.Tang M, Hu X, Wang Y, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 2021. PMID 32971268
  15. 15.Morinaga S, Han Q, Mizuta K, et al. Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells. Anticancer Research, 2025. PMID 39740811
  16. 16.Sarafraz-Yazdi E, Bowne WB, Adler V, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. PNAS, 2010. PMID 20080680
  17. 17.Sarafraz-Yazdi E, Pincus MR, Michl J PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines, 2022. PMID 35625682
  18. 18.Sookraj KA, Bowne WB, Adler V, et al. The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide. Cancer Chemotherapy and Pharmacology, 2010. PMID 20182728
  19. 19.Davitt K, Babcock BD, Fenelus M, et al. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Annals of Clinical and Laboratory Science, 2014. PMID 25117093

Other conditions Rottweilers are predisposed to: Hip dysplasia, Osteoarthritis, Cranial cruciate ligament (CCL) tear.

Where to source research peptides

Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.

Visit Pet & Peps Research →How to evaluate a supplier

Educational information — not veterinary medical advice

Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.